Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 5756102, 9 pages
https://doi.org/10.1155/2017/5756102
Research Article

Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases

1Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
2Department of Pathology, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang 310014, China
3Jiading District Center for Disease Control and Prevention, Shanghai 201800, China

Correspondence should be addressed to Jianlin Lou; moc.361@uolnilnaij

Received 3 November 2016; Revised 11 January 2017; Accepted 19 January 2017; Published 1 March 2017

Academic Editor: Vincent Sapin

Copyright © 2017 Shibo Ying et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Takahashi, P. J. Landrigan, and R. Collegium, “The global health dimensions of asbestos and asbestos-related diseases,” Annals of Global Health, vol. 82, no. 1, pp. 209–213, 2016. View at Publisher · View at Google Scholar
  2. M. N. Courtice, S. Lin, and X. Wang, “An updated review on asbestos and related diseases in China,” International Journal of Occupational and Environmental Health, vol. 18, no. 3, pp. 247–253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E.-K. Park, K. Takahashi, Y. Jiang, M. Movahed, and T. Kameda, “Elimination of asbestos use and asbestos-related diseases: an unfinished story,” Cancer Science, vol. 103, no. 10, pp. 1751–1755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Naglova and M. Bucova, “HMGB1 and its physiological and pathological roles,” Bratislavské Lekárske Listy, vol. 113, no. 3, pp. 163–171, 2012. View at Google Scholar · View at Scopus
  5. R. Kang, Q. Zhang, H. J. Zeh III, M. T. Lotze, and D. Tang, “HMGB1 in cancer: good, bad, or both?” Clinical Cancer Research, vol. 19, no. 15, pp. 4046–4057, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. G. P. Sims, D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle, “HMGB1 and RAGE in inflammation and cancer,” Annual Review of Immunology, vol. 28, pp. 367–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Nogueira-Machado, C. M. D. O. Volpe, C. A. Veloso, and M. M. Chaves, “HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation,” Expert Opinion on Therapeutic Targets, vol. 15, no. 8, pp. 1023–1035, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Yang, Z. Rivera, S. Jube et al., “Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12611–12616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Carbone and H. Yang, “Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma,” Clinical Cancer Research, vol. 18, no. 3, pp. 598–604, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Albayrak, A. Albayrak, M. Celik et al., “High mobility group box protein-1 (HMGB-1) as a new diagnostic marker in patients with acute appendicitis,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, vol. 19, article 27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Resman Rus, L. Fajs, M. Korva, and T. Avšič-Županc, “HMGB1 is a potential biomarker for severe viral hemorrhagic fevers,” PLoS Neglected Tropical Diseases, vol. 10, no. 6, Article ID e0004804, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Nogueira-Machado and C. M. de Oliveira Volpe, “HMGB-1 as a target for inflammation controlling,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 6, no. 3, pp. 201–209, 2012. View at Publisher · View at Google Scholar
  13. Y. Li, J. Tian, X. Fu et al., “Serum high mobility group box protein 1 as a clinical marker for ovarian cancer,” Neoplasma, vol. 61, no. 5, pp. 579–584, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Paek, M. Lee, E. J. Nam, S. W. Kim, and Y. T. Kim, “Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer,” Archives of Gynecology and Obstetrics, vol. 293, no. 3, pp. 645–650, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Pang, Y. Zhang, H. Wei et al., “Expression and effects of high-mobility group box 1 in cervical cancer,” International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8699–8712, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. G.-H. Shang, C.-Q. Jia, H. Tian et al., “Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer,” Respiratory Medicine, vol. 103, no. 12, pp. 1949–1953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Sun, W. Zhang, Z. Cui et al., “High mobility group box-1 and its clinical value in breast cancer,” OncoTargets and Therapy, vol. 8, pp. 413–419, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Süren, M. Yildirim, Ö. Demirpençe et al., “The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer,” Medical Science Monitor, vol. 20, pp. 530–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Ueda, Y. Takahashi, Y. Shinden et al., “Prognostic significance of High Mobility Group Box 1 (HMGB1) expression in patients with colorectal cancer,” Anticancer Research, vol. 34, no. 10, pp. 5357–5362, 2014. View at Google Scholar · View at Scopus
  20. S. Jube, Z. S. Rivera, M. E. Bianchi et al., “Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma,” Cancer Research, vol. 72, no. 13, pp. 3290–3301, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Tabata, S. Kanemura, R. Tabata et al., “Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma,” Journal of Clinical Gastroenterology, vol. 47, no. 8, pp. 684–688, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Tabata, E. Shibata, R. Tabata et al., “Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma,” BMC Cancer, vol. 13, article 205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Gao, K. Hiroshima, X. Wu et al., “Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: analysis of 28 cases in Southeast China,” American Journal of Industrial Medicine, vol. 58, no. 10, pp. 1040–1049, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. D. D. Smith, “Diagnosis and initial management of nonmalignant diseases related to asbestos,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 6, pp. 691–715, 2005. View at Google Scholar
  25. A. N. Husain, T. Colby, N. Ordonez et al., “Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group,” Archives of Pathology and Laboratory Medicine, vol. 137, no. 5, pp. 647–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Yu, Y. Zhang, Z. Jiang et al., “Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population,” Environmental Health and Preventive Medicine, vol. 20, no. 5, pp. 369–378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. P.-L. Liu, J.-R. Tsai, J.-J. Hwang et al., “High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness,” American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 5, pp. 530–538, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Qiu, J. Xu, Y. Zheng et al., “High-mobility group box 1 promotes metalloproteinase-9 upregulation through toll-like receptor 4 after cerebral ischemia,” Stroke, vol. 41, no. 9, pp. 2077–2082, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Sapojnikova, T. Kartvelishvili, N. Asatiani et al., “Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome,” Biochimica et Biophysica Acta, vol. 1842, no. 9, pp. 1379–1384, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-L. Wang, D.-W. Wu, Z.-Z. Cheng, W.-Z. Han, S.-W. Xu, and N.-N. Sun, “Expression of High Mobility Group Box-B1 (HMGB-1) and Matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC),” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 12, pp. 4865–4869, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. H.-M. Chen, S.-F. Liou, J.-H. Hsu et al., “Baicalein inhibits HMGB1 release and MMP-2/-9 expression in lipopolysaccharide-induced cardiac hypertrophy,” American Journal of Chinese Medicine, vol. 42, no. 4, pp. 785–797, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Tang, R. Kang, H. J. Zeh III, and M. T. Lotze, “High-mobility group box 1 and cancer,” Biochimica et Biophysica Acta, vol. 1799, no. 1-2, pp. 131–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Qi, G. Okimoto, S. Jube et al., “Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling,” The American Journal of Pathology, vol. 183, no. 5, pp. 1654–1666, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. T. A. Sporn, “Mineralogy of asbestos,” Recent Results in Cancer Research, vol. 189, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. Englert, L. E. Hanford, N. Kaminski et al., “A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis,” American Journal of Pathology, vol. 172, no. 3, pp. 583–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Englert, C. R. Kliment, L. Ramsgaard et al., “Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 3, pp. 241–254, 2011. View at Google Scholar · View at Scopus
  37. D. Musumeci, G. N. Roviello, and D. Montesarchio, “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies,” Pharmacology and Therapeutics, vol. 141, no. 3, pp. 347–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Cheng, W. Dai, F. Wang et al., “Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways,” Biochemical and Biophysical Research Communications, vol. 443, no. 4, pp. 1162–1168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. J.-H. Shin, I.-D. Kim, S.-W. Kim et al., “Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium,” Molecular Medicine, vol. 20, pp. 649–657, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Ying, X. Xiao, T. Chen, and J. Lou, “PPAR ligands function as suppressors that target biological actions of HMGB1,” PPAR Research, vol. 2016, Article ID 2612743, 10 pages, 2016. View at Publisher · View at Google Scholar
  41. A. Bononi, A. Napolitano, H. I. Pass, H. Yang, and M. Carbone, “Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies,” Expert Review of Respiratory Medicine, vol. 9, no. 5, pp. 633–654, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Napolitano, D. J. Antoine, L. Pellegrini et al., “HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients,” Clinical Cancer Research, vol. 22, no. 12, pp. 3087–3096, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. S. X. Cai, C. H. Zhang, X. Zhang, and K. Morinaga, “Epidemiology of occupational asbestos-related diseases in China,” Industrial Health, vol. 39, no. 2, pp. 75–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Yano, Z.-M. Wang, X.-R. Wang et al., “Mesothelioma in a worker who spun chrysotile asbestos at home during childhood,” American Journal of Industrial Medicine, vol. 52, no. 4, pp. 282–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. R. P. Verma and C. Hansch, “Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs,” Bioorganic and Medicinal Chemistry, vol. 15, no. 6, pp. 2223–2268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Cathcart, A. Pulkoski-Gross, and J. Cao, “Targeting matrix metalloproteinases in cancer: bringing new life to old ideas,” Genes and Diseases, vol. 2, no. 1, pp. 26–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Sivakumar, P. Ntolios, G. Jenkins, and G. Laurent, “Into the matrix: targeting fibroblasts in pulmonary fibrosis,” Current Opinion in Pulmonary Medicine, vol. 18, no. 5, pp. 462–469, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Amati, M. Tomasetti, M. Scartozzi et al., “Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 1, pp. 163–170, 2008. View at Publisher · View at Google Scholar · View at Scopus